NF-κB Activation Inhibitor III is a thiazoloamide compound experimentally shown to inhibit TNF-α-stimulated NF-κB activation and MMP-9 in HT1080 upregulation. This upregulation corresponds to a concomitant inhibition of TNF-α-dependent cellular invasion. This compound has not been shown to affect the TNF-α-induced AP-1, occurring downstream of p38 activation.
1. Lee, H.Y., et al. 2005. Biochem. Biophys. Res. Commun. 336: 716-722. PMID: 16140265
See how others have used NFkappaB Activation Inhibitor III. Click on the entry to view the PubMed entry .
PMID: # 23592398 Sun, L. et al. 2013. Stem cells (Dayton, Ohio). 31: 1454-66.
PMID: # 16140265 Lee, HY. et al. 2005. Biochem. Biophys. Res. Commun. 336: 716-722.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.